RU2013119869A - Аналоги циклоспорина - Google Patents
Аналоги циклоспорина Download PDFInfo
- Publication number
- RU2013119869A RU2013119869A RU2013119869/04A RU2013119869A RU2013119869A RU 2013119869 A RU2013119869 A RU 2013119869A RU 2013119869/04 A RU2013119869/04 A RU 2013119869/04A RU 2013119869 A RU2013119869 A RU 2013119869A RU 2013119869 A RU2013119869 A RU 2013119869A
- Authority
- RU
- Russia
- Prior art keywords
- cyclosporin
- cap
- chr
- branched
- ethyl
- Prior art date
Links
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical class CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 title claims 59
- 150000001875 compounds Chemical class 0.000 claims abstract 23
- -1 2-hydroxyisobutyl Chemical group 0.000 claims abstract 13
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims abstract 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract 9
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 9
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract 8
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 8
- 239000011593 sulfur Substances 0.000 claims abstract 8
- 125000003118 aryl group Chemical group 0.000 claims abstract 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract 7
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 7
- 125000005842 heteroatom Chemical group 0.000 claims abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 7
- 239000001257 hydrogen Substances 0.000 claims abstract 7
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract 7
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims abstract 7
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 7
- 239000001301 oxygen Chemical group 0.000 claims abstract 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 5
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 claims abstract 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims abstract 5
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims abstract 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims abstract 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims abstract 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 3
- 150000002431 hydrogen Chemical class 0.000 claims abstract 3
- 229910052736 halogen Inorganic materials 0.000 claims abstract 2
- 150000002367 halogens Chemical class 0.000 claims abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract 2
- 229920006395 saturated elastomer Polymers 0.000 claims abstract 2
- 229930105110 Cyclosporin A Natural products 0.000 claims 58
- 108010036949 Cyclosporine Proteins 0.000 claims 58
- 229960001265 ciclosporin Drugs 0.000 claims 58
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims 8
- 101150065749 Churc1 gene Proteins 0.000 claims 8
- 102100038239 Protein Churchill Human genes 0.000 claims 8
- 238000000034 method Methods 0.000 claims 6
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 3
- 210000004087 cornea Anatomy 0.000 claims 3
- 206010023332 keratitis Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- ZNVBEWJRWHNZMK-SYOLRUPNSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21,30-tri(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,2 Chemical compound C\C=C\C[C@@H](C)[C@@H](O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](C(C)C)NC1=O ZNVBEWJRWHNZMK-SYOLRUPNSA-N 0.000 claims 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 108010019594 cyclosporin D Proteins 0.000 claims 2
- 201000010666 keratoconjunctivitis Diseases 0.000 claims 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical group [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 206010003645 Atopy Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 1
- 206010013774 Dry eye Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 208000009889 Herpes Simplex Diseases 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims 1
- 206010072139 Ocular rosacea Diseases 0.000 claims 1
- 201000002154 Pterygium Diseases 0.000 claims 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 208000016807 X-linked intellectual disability-macrocephaly-macroorchidism syndrome Diseases 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 206010069664 atopic keratoconjunctivitis Diseases 0.000 claims 1
- 208000010217 blepharitis Diseases 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims 1
- 239000001569 carbon dioxide Substances 0.000 claims 1
- 229910002092 carbon dioxide Inorganic materials 0.000 claims 1
- JYWJULGYGOLCGW-UHFFFAOYSA-N chloromethyl chloroformate Chemical compound ClCOC(Cl)=O JYWJULGYGOLCGW-UHFFFAOYSA-N 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 206010015907 eye allergy Diseases 0.000 claims 1
- 208000027993 eye symptom Diseases 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 210000004175 meibomian gland Anatomy 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000015200 ocular cicatricial pemphigoid Diseases 0.000 claims 1
- 238000010791 quenching Methods 0.000 claims 1
- 230000000171 quenching effect Effects 0.000 claims 1
- 239000011541 reaction mixture Substances 0.000 claims 1
- 201000004700 rosacea Diseases 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C07K7/645—Cyclosporins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Virology (AREA)
- Ophthalmology & Optometry (AREA)
- Analytical Chemistry (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39244910P | 2010-10-12 | 2010-10-12 | |
| US61/392,449 | 2010-10-12 | ||
| PCT/US2011/055791 WO2012051194A1 (en) | 2010-10-12 | 2011-10-11 | Cyclosporin analogs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013119869A true RU2013119869A (ru) | 2014-11-20 |
Family
ID=44883784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013119869/04A RU2013119869A (ru) | 2010-10-12 | 2011-10-11 | Аналоги циклоспорина |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20120088734A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2627664B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP5805774B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20140026329A (cg-RX-API-DMAC7.html) |
| CN (1) | CN103328497A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2011316690C1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112013008864A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2814192A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL225617A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2013004061A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2013119869A (cg-RX-API-DMAC7.html) |
| SG (1) | SG189880A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012051194A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9573978B2 (en) | 2010-08-12 | 2017-02-21 | S&T Global, Inc. | Cyclosporin derivatives for the treatment and prevention of a viral infection |
| WO2012051194A1 (en) * | 2010-10-12 | 2012-04-19 | Allergan, Inc. | Cyclosporin analogs |
| CN103261212A (zh) | 2010-10-12 | 2013-08-21 | 阿勒根公司 | 环孢菌素类似物 |
| US9890198B2 (en) * | 2010-12-03 | 2018-02-13 | S&T Global Inc. | Cyclosporin derivatives and uses thereof |
| AU2011342284C1 (en) * | 2010-12-15 | 2017-07-13 | Contravir Pharmaceuticals, Inc. | Cyclosporine analogue molecules modified at amino acid 1 and 3 |
| CN104487449A (zh) * | 2012-06-01 | 2015-04-01 | 阿勒根公司 | 环孢菌素a类似物 |
| GB201222455D0 (en) * | 2012-12-13 | 2013-01-30 | Perioc Ltd | Novel pharmaceutical formulations and their use in the treatment of periodontaldisease |
| WO2014138437A1 (en) | 2013-03-08 | 2014-09-12 | Allergan, Inc. | Steroid conjugates |
| WO2016112321A1 (en) | 2015-01-08 | 2016-07-14 | Allergan, Inc. | Cyclosporin derivatives wherein the mebmt sidechain has been cyclized |
| EP3277704A1 (en) | 2015-03-31 | 2018-02-07 | Allergan, Inc. | Cyclosporins modified on the mebmt sidechain by heterocyclic rings |
| JP2019518745A (ja) * | 2016-05-17 | 2019-07-04 | エス アンド ティー グローバル インク． | 新規シクロスポリン誘導体及びその使用 |
| US20180193003A1 (en) | 2016-12-07 | 2018-07-12 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
| US11523772B2 (en) | 2016-12-14 | 2022-12-13 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with an immunosuppressant |
| US20230041197A1 (en) | 2018-06-20 | 2023-02-09 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| WO2021173474A1 (en) * | 2020-02-26 | 2021-09-02 | Bacainn Biotherapeutics, Ltd. | Cyclosporine compositions and methods of use |
| CN113173974B (zh) * | 2021-03-18 | 2024-09-06 | 北京大学深圳研究生院 | 环孢素衍生物的合成方法 |
| WO2024254480A2 (en) * | 2023-06-08 | 2024-12-12 | Hepion Pharmaceuticals, Inc. | Solid state forms of rencofilstat |
| CN118834148B (zh) * | 2024-09-20 | 2025-01-21 | 天津凯莱英制药有限公司 | 一种l-青霉胺的制备方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0194972B1 (en) | 1985-03-11 | 1992-07-29 | Sandoz Ag | Novel cyclosporins |
| US4649047A (en) * | 1985-03-19 | 1987-03-10 | University Of Georgia Research Foundation, Inc. | Ophthalmic treatment by topical administration of cyclosporin |
| US4839342A (en) | 1987-09-03 | 1989-06-13 | University Of Georgia Research Foundation, Inc. | Method of increasing tear production by topical administration of cyclosporin |
| US5474979A (en) * | 1994-05-17 | 1995-12-12 | Allergan, Inc. | Nonirritating emulsions for sensitive tissue |
| FR2757521B1 (fr) | 1996-12-24 | 1999-01-29 | Rhone Poulenc Rorer Sa | Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent |
| FR2757522B1 (fr) | 1996-12-24 | 1999-01-29 | Rhone Poulenc Rorer Sa | Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent |
| FR2762843B1 (fr) | 1997-04-30 | 1999-12-10 | Rhone Poulenc Rorer Sa | Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent |
| HUP0102833A3 (en) * | 1998-06-12 | 2002-03-28 | Chem Ag C | Cyclosporins, process for preparation thereof and their use |
| US6254860B1 (en) * | 1999-04-13 | 2001-07-03 | Allergan Sales, Inc. | Ocular treatment using cyclosporin-A derivatives |
| US20050059583A1 (en) * | 2003-09-15 | 2005-03-17 | Allergan, Inc. | Methods of providing therapeutic effects using cyclosporin components |
| US7676680B2 (en) | 2005-07-08 | 2010-03-09 | Morgan Stanley | Systems and methods for distributing private placement documents |
| US7288520B2 (en) | 2005-07-13 | 2007-10-30 | Allergan, Inc. | Cyclosporin compositions |
| DK2023918T3 (da) | 2006-05-19 | 2011-04-26 | Scynexis Inc | Cyclosporiner til behandlingen og forebyggelse af okulære lidelser |
| CN101130058B (zh) * | 2006-08-23 | 2011-10-05 | 华北制药集团新药研究开发有限责任公司 | 一种环孢菌素a眼用乳剂及其制备方法 |
| CN101687013A (zh) * | 2007-05-04 | 2010-03-31 | 阿勒根公司 | 环孢菌素在治疗具有人工晶状体的患者中的用途 |
| BRPI0915552A2 (pt) * | 2008-07-10 | 2017-06-20 | Allergan Inc | derivados de ciclosporina, seu uso e sua composição farmacêutica |
| WO2012003077A1 (en) * | 2010-07-02 | 2012-01-05 | Exxonmobil Upstream Research Company | Low emission triple-cycle power generation systems and methods |
| US8902844B2 (en) | 2010-07-06 | 2014-12-02 | Lg Electronics Inc. | Method and device for allocating wireless resources for a machine type communication device in a wireless communication system |
| WO2012051194A1 (en) * | 2010-10-12 | 2012-04-19 | Allergan, Inc. | Cyclosporin analogs |
| US9890198B2 (en) | 2010-12-03 | 2018-02-13 | S&T Global Inc. | Cyclosporin derivatives and uses thereof |
| ES2625502T3 (es) * | 2010-12-03 | 2017-07-19 | S&T Global Inc | Nuevos derivados de ciclosporina para el tratamiento y prevención de una infección vírica |
| CN103987399A (zh) * | 2011-08-19 | 2014-08-13 | 美国科技环球有限公司 | 用于治疗和预防病毒感染的新型环孢菌素衍生物 |
-
2011
- 2011-10-11 WO PCT/US2011/055791 patent/WO2012051194A1/en not_active Ceased
- 2011-10-11 KR KR1020137012145A patent/KR20140026329A/ko not_active Withdrawn
- 2011-10-11 EP EP11770985.7A patent/EP2627664B1/en not_active Not-in-force
- 2011-10-11 CA CA2814192A patent/CA2814192A1/en not_active Abandoned
- 2011-10-11 BR BR112013008864A patent/BR112013008864A2/pt not_active Application Discontinuation
- 2011-10-11 RU RU2013119869/04A patent/RU2013119869A/ru not_active Application Discontinuation
- 2011-10-11 SG SG2013027339A patent/SG189880A1/en unknown
- 2011-10-11 CN CN2011800596461A patent/CN103328497A/zh active Pending
- 2011-10-11 MX MX2013004061A patent/MX2013004061A/es unknown
- 2011-10-11 JP JP2013533942A patent/JP5805774B2/ja not_active Expired - Fee Related
- 2011-10-11 AU AU2011316690A patent/AU2011316690C1/en not_active Ceased
- 2011-10-11 US US13/270,964 patent/US20120088734A1/en not_active Abandoned
-
2013
- 2013-04-07 IL IL225617A patent/IL225617A0/en unknown
-
2014
- 2014-11-06 US US14/534,677 patent/US9493511B2/en active Active
-
2015
- 2015-09-02 JP JP2015173082A patent/JP6250608B2/ja not_active Expired - Fee Related
-
2016
- 2016-10-11 US US15/290,171 patent/US10065992B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011316690B2 (en) | 2016-07-07 |
| EP2627664B1 (en) | 2018-04-04 |
| JP6250608B2 (ja) | 2017-12-20 |
| US20120088734A1 (en) | 2012-04-12 |
| WO2012051194A1 (en) | 2012-04-19 |
| AU2011316690A1 (en) | 2013-05-02 |
| SG189880A1 (en) | 2013-06-28 |
| JP2016029050A (ja) | 2016-03-03 |
| KR20140026329A (ko) | 2014-03-05 |
| US10065992B2 (en) | 2018-09-04 |
| CA2814192A1 (en) | 2012-04-19 |
| IL225617A0 (en) | 2013-06-27 |
| CN103328497A (zh) | 2013-09-25 |
| JP5805774B2 (ja) | 2015-11-10 |
| EP2627664A1 (en) | 2013-08-21 |
| MX2013004061A (es) | 2013-07-22 |
| BR112013008864A2 (pt) | 2016-06-28 |
| US9493511B2 (en) | 2016-11-15 |
| JP2013540776A (ja) | 2013-11-07 |
| US20150065433A1 (en) | 2015-03-05 |
| AU2011316690C1 (en) | 2017-01-19 |
| US20170029469A1 (en) | 2017-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013119869A (ru) | Аналоги циклоспорина | |
| JP2013540776A5 (cg-RX-API-DMAC7.html) | ||
| JP4217832B2 (ja) | 角結膜障害の治療剤 | |
| RU2013120927A (ru) | Аналоги циклоспорина | |
| JP5827327B2 (ja) | リン酸輸送を阻害する化合物及び方法 | |
| JP2016506391A (ja) | ペプチド治療薬およびその使用方法 | |
| FI3678705T3 (fi) | Montelukastin ja peptidien konjugaatteja | |
| JP2013544786A5 (cg-RX-API-DMAC7.html) | ||
| RU2468793C2 (ru) | Композиции на основе соединений 2-амино-1,3-пропандиола | |
| JP6771698B1 (ja) | ウルソデオキシコール酸を含有する老視の治療または予防剤 | |
| RU2004100535A (ru) | Способы и материалы для лечения тестостероновой недостаточности у мужчин | |
| JP6397477B2 (ja) | 白内障及び老眼を阻害する方法 | |
| WO2008087461B1 (en) | Use of kynurenic acid and derivatives thereof in the treatment of conditions of the gastrointestinal tract accompanied by hypermotility and inflammation or gout or multiple sclerosis | |
| AU2011298430B2 (en) | Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension | |
| EA201992744A1 (ru) | Фармацевтические композиции n-(2-(2-(диметиламино)этокси)-4-метокси-5-((4-(1-метил-1h-индол-3-ил)пиримидин-2-ил)амино)фенил)акриламида и его солей | |
| WO2020129965A1 (ja) | ４－フェニル酪酸を含有する老視の治療または予防剤 | |
| JP6781974B2 (ja) | アドレノメデュリン凍結乾燥製剤の製造方法 | |
| CN104974221B (zh) | 二肽及三肽类蛋白酶体抑制剂及其制法和药物用途 | |
| JP6509244B2 (ja) | 水晶体硬化抑制剤 | |
| JP6143270B2 (ja) | マイオスタチン阻害ペプチド | |
| US20110151025A1 (en) | Compositions Comprising N-Halogenated or N,N-Dihalogenated Amine for Treatment and Prophylaxis of Bronchopulmonary Infections | |
| JP2003231695A (ja) | 新規ペプチドおよびその医薬用途 | |
| JP2022152866A (ja) | コール酸またはコール酸誘導体を含有する老視の治療または予防剤 | |
| WO2025000280A1 (zh) | 预防或治疗犬科骨或关节疾病的化合物、组合物及用途 | |
| WO2024218649A3 (en) | Combination of a protein kinase inhibitor with immunomodulatory agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20141013 |